CD274 and neoplasm: Clinical evidence from retrospective cohorts and early prospective studies supports ERV signatures as biomarkers for immune checkpoint inhibitor (ICI) response, often independent of PD-L1 or tumor mutational burden, and enables ERV-based stratification.